[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363007-105":59,"doc-detail-363007-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","fluorine-18-labeled-nucleotide-analogs-targeting-ecto-5-nucleotidase-cd73-for-positron-emission-tomography-imaging-of-solid-tumors","Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5’-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors","","Ecto-5’-nucleotidase (CD73) is presented as a promising drug target for cancer immunotherapy because its overexpression correlates with aggressive malignancies, including triple-negative breast cancer and pancreatic cancer. Small-molecule CD73 inhibitors have progressed toward clinical testing, motivating development of fluorine-18 labeled high-affinity CD73 inhibitors for PET imaging of CD73 expression. Two candidates with high potency and favorable pharmacokinetics produced radiotracers that showed specific ex vivo binding and in vivo performance. One tracer demonstrated superior accumulation and elimination characteristics, with advantages over [18F]FDG for visualizing TNBC, supporting broad solid-tumor diagnostic use.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fluorine-18-labeled-nucleotide-analogs-targeting-ecto-5-nucleotidase-cd73-for-positron-emission-tomography-imaging-of-solid-tumors/363007/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fluorine-18-labeled-nucleotide-analogs-targeting-ecto-5-nucleotidase-cd73-for-positron-emission-tomography-imaging-of-solid-tumors/363007.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the study’s main goal?","Question",{"text":113,"@type":114},"To develop and evaluate fluorine-18 labeled, high-affinity CD73 inhibitors as PET tracers for imaging CD73 expression in cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which radiotracers were selected for radiolabeling and why?",{"text":118,"@type":114},"Two CD73 inhibitors were chosen due to high potency (about 1 nM Ki) and favorable pharmacokinetic properties, yielding [18F]PSB-19427 ([18F]1) and [18F]MRS-4648 ([18F]2).",{"name":120,"@type":111,"acceptedAnswer":121},"How did the tracers perform in ex vivo and in vivo studies?",{"text":122,"@type":114},"Ex vivo imaging showed specific binding of both radiotracers to human breast cancer tissues, while in vivo results indicated [18F]1 was superior, with stronger suitability for imaging TNBC and pancreatic cancer.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363007,1790270609,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Angew Chem Int Ed Engl. Author manuscript; available in PMC 2026 April 15. |\n| --- | --- |\n\nPublished in final edited form as:  \nAngew Chem Int Ed Engl. 2026 April 20; 65(17): e22758 . doi:10.1002/anie.202522758 .  \nFluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5’-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors  \nClemens Dobelmann 1 , Constanze C. Schmies2 , Georg Wilhelm Rolshoven2 , Mirko Scortichini3 , Stefan Wagner4 , Andreas Isaak1 , Riham M. Idris2 , Jennifer Dabel 1 , Lucie Grey5 , Karolina Losenkova6 , Susanne Moschütz7 , Haneen Al Hroub2 , Antje Keim7 , Sandra Höppner1 , Jouko Sandholm8 , Pia Boström9 , Maija Hollmén6 , Norbert Sträter7 , Sven Hermann 1 , Gennady G. Yegutkin6 , Kenneth A. Jacobson3 , Sonja Schelhaas 1 , Christa E. Müller2 , Anna Junker1,10  \n1 European Institute for Molecular Imaging (EIMI), University of Muenster, Münster, Germany  \n2 PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry University of Bonn, Bonn, Germany  \n3Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA  \n4 Department of Nuclear Medicine, University Hospital Muenster, Münster, Germany  \n5 Institut Für Pharmazeutische und Medizinische Chemie, University of Muenster, Muenster, Germany  \n6Medicity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland  \n7 Institute of Bioanalytical Chemistry, Center for Biotechnology and Biomedicine, Leipzig University, Leipzig, Germany  \n8Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland  \n9 Department of Pathology, University of Turku and Turku University Central Hospital, Turku, Finland  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nCorrespondence: Christa E. Müller ([christa.mueller@uni-bonn.de](christa.mueller@uni-bonn.de)), Anna Junker ([anna.junker@med.uni-tuebingen.de](anna.junker@med.uni-tuebingen.de)).  \nAuthor Contributions  \nConceptualization: Anna Junker, Christa E. Muller. Methodology: Anna Junker, Christa E. Muller. Investigation: Anna Junker, Clemens Dobelmann, Stefan Wagner, Lucie Grey, Jennifer Dabel, Andreas Isaak, Constanze C. Schmies, Georg W. Rolshoven, and Mirko Scortichini. Visualization: Sonja Schelhaas, Sandra Hoppner, and Gennady G. Yegutkin, Funding Acquisition: Anna Junker, Christa E. Muller. Project Administration: Anna Junker. Supervision: Anna Junker, Kenneth A. Jacobson, Christa E. Muller, and Sonja Schelhaas. Writing—Original Draft: Anna Junker, Christa E. Muller. Writing—Review & Editing: Anna Junker, Christa E. Muller, with support from all coauthors, who also reviewed and edited the manuscript.  \nClemens Dobelmann and Constanze C. Schmies contributed equally to this work.  \nConflicts of Interest  \nThe authors declare no conflicts of interest. Anna Junker, Kenneth A. Jacobson, and Christa E. Muller are coinventors on patent no. WO2020/037275A1.Anna Junker, Clemens Dobelmann, Christa E. Müller, Sonja Schelhaas, Sandra Höppner, and Stefan Wagner are coinventors on patent no. PCT/EP2023/054046 .  \nAuthor Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \nDobelmann et al. Page 2  \n10Werner Siemens Imaging Center, Eberhard Karls University of Tuebingen, Department of Preclinical Imaging and Radiopharmacy; Cluster of Excellence iFIT (EXC 2180), Image-Guided and Functionally Instructed Tumor Therapies, Tuebingen, Germany  \nAbstract  \nEcto-5’-nucleotidase (CD73) is a potential new drug target for cancer immunotherapy. Its overexpression is associated with various aggressive cancers, including triple-negative breast c","cbCainoPeMCNpVcv","https://ap.wps.com/l/cbCainoPeMCNpVcv","pdf",2997308,27,"English","# Abstract\n# Introduction","[{\"question\":\"What is the study’s main goal?\",\"answer\":\"To develop and evaluate fluorine-18 labeled, high-affinity CD73 inhibitors as PET tracers for imaging CD73 expression in cancer.\"},{\"question\":\"Which radiotracers were selected for radiolabeling and why?\",\"answer\":\"Two CD73 inhibitors were chosen due to high potency (about 1 nM Ki) and favorable pharmacokinetic properties, yielding [18F]PSB-19427 ([18F]1) and [18F]MRS-4648 ([18F]2).\"},{\"question\":\"How did the tracers perform in ex vivo and in vivo studies?\",\"answer\":\"Ex vivo imaging showed specific binding of both radiotracers to human breast cancer tissues, while in vivo results indicated [18F]1 was superior, with stronger suitability for imaging TNBC and pancreatic cancer.\"}]","Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5’-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors | PDF",1790149649,68,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c08a02c328a6a5fcc4afb3db5cd95e0a.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1357b0435602f90dbd6eabe2f6215a65.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6811642ec05dcbfca7e82175d0adf1c5.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/816952f361ef17dec2c814270294bf67.webp",980,1268]